TIGIT and neoplasm: In DLBCL-type RT, CD226, a TIGIT competitor that activates T and NK cells via CD155, is abnormally elevated, suggesting an imbalance favoring activating signals in DLBCL-type RT tumor cells, contrasting with higher TIGIT levels in CLL cells [96,97,98].